Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease

BACKGROUND AND AIM: E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation. We evaluated the safety and pharmacokinetic profile of E6011 in patients with Crohn's disease (CD) and also performed preliminar...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Katsuyoshi, Naganuma, Makoto, Hibi, Toshifumi, Tsubouchi, Hirohito, Oketani, Kiyoshi, Katsurabara, Toshinori, Hojo, Seiichiro, Takenaka, Osamu, Kawano, Tetsu, Imai, Toshio, Kanai, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451784/
https://www.ncbi.nlm.nih.gov/pubmed/33599356
http://dx.doi.org/10.1111/jgh.15463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451784/
https://www.ncbi.nlm.nih.gov/pubmed/33599356
http://dx.doi.org/10.1111/jgh.15463

Ejemplares similares